Recent cancellation of federally funded grants results in significant changes for the university's global health activities ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations.

The cancellation of USAID contracts has threatened critical global health research. Plus, new guidance to prevent HIV in ...

Aid agencies distributing U.S. food aid in Ethiopia's war-affected Tigray region say they have had to stop feeding millions ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

Unlike President Trump's picks to lead other health agencies who established their conservative bona fides during the ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...